tx 3301 has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bdiiwi, S; Boison, D; Boktor, H; Castro, D; Dadario, NB; Finkle, D; Greenberg, P; Khandelwal, P; Koziol, J; Kyi, HH; Libutti, SK; Liu, J; Ly, K; Malhotra, R; Maninderpal, K; Nanda, A; Nipun, S; Patel, S; Patrawalla, A; Singla, A; Sonig, A; Subanna, S; Sutherland, A; Xie, Y; Yan, R | 1 |
1 trial(s) available for tx 3301 and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection.
Topics: Antiviral Agents; Aspirin; Aspirin, Dipyridamole Drug Combination; COVID-19; Female; Humans; SARS-CoV-2; Treatment Outcome | 2023 |